Compare Sana Biotechnology Inc (SANA) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs VNET Group Inc — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while VNET Group Inc trades at $6.57 (market cap $1.92B). The key difference: VNET Group Inc is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VNET | |
|---|---|---|
Market Cap | $1.03B | $1.92B |
Sector | Health | Technology |
52-Week High | $5.92 | $14.03 |
52-Week Low | $2.68 | $6.06 |
Enterprise Value | $946.04M | $5.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
VNET Group trades at $6.75, up 5.97% today, amid bearish technical signals and mixed fundamentals. The company reported Q2 2026 revenue growth driven by wholesale data center demand but missed earnings expectations with a net loss. Despite a strategic partnership with CATL announced August 2026, negative profit margins and rising leverage remain concerns. Analyst consensus is bullish with 62.5% buy ratings, though technical indicators show selling pressure.
Outlook: Growth potential exists from AI infrastructure demand and new capacity, but high debt and consistent losses pose significant risks. Investors should weigh strong institutional support against fundamental weaknesses and ongoing class action litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
